OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	216
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	157
Steroid tapering after GVHD Rx: not too fast, not too slow	156
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	145
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	142
Addressing and overcoming disparities in GVHD	127
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	125
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	122
On a collision course: SARS-CoV-2 variants and CAR T cells	119
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	108
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	107
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	107
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	101
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	99
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	97
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	97
Priapism Before and After Hematopoietic Stem Cell Therapy in Individuals with Sickle Cell Disease	95
Complement C5 inhibition in early onset HELLP syndrome	92
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	91
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	91
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	90
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	86
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	82
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	82
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	81

Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene Autotemcel	81
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	79
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	79
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	77
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	74
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	70
Cortisol in sickle cell disease: a systematic review and meta-analysis	69
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	69
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	68
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	68
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	68
Outcomes with Third Party Virus Specific T-cells After the Use of Single Antigen Cell Lines to Predict HLA Restriction	67
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	67
Transfusion therapy for sickle cell disease: what’s new?	65
Bite-size introduction to canine hematologic malignancies	65
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	65
Best but not perfect: indirect measure of low iron stores	63
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	63
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	63
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	63
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	62
Applying CRISPR-Cas9 screens to dissect hematological malignancies	61
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	61
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	61
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	61
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	59
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	59
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	59
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	59
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	59
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	59
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	59
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	58